2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 402

The Risk of Hospitalized Infection Associated with Initiation of Abatacept Versus TNF Inhibitors in Juvenile Idiopathic Arthritis
Abstract Number: 403

High Rate of Serious Infection in Juvenile Idiopathic Arthritis Under Biologic Therapy in a Real Life Setting
Abstract Number: 404

Disease Activity and Damage in Juvenile Idiopathic Arthritis: Comparison Between “Methotrexate” and “Biologic” Era
Abstract Number: 405

Patterns of Medication Use in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry
Abstract Number: 406

Adults with Juvenile Idiopathic Arthritis Are Not Adults with Rheumatoid Arthritis
Abstract Number: 407

Comparability of Proxy, Adolescent and Adult Measures of Functional Ability in Adolescents with JIA
Abstract Number: 408

Development and Initial Validation of the Parent and Child Versions of the Juvenile Arthritis Disease Activity Score
Abstract Number: 409

Discordance Between Physician, Patient, and Parent Disease Assessment Scores in Juvenile Idiopathic Arthritis
Abstract Number: 410

Sleep and Its Relationship to Pain and Disease Activity in Turkish Children and Adolescent with Juvenile Idiopathic Arthritis
Abstract Number: 411

Evaluating Levels of Activity and Health-Related Quality of Life in a Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
Abstract Number: 412

Oral Glucocorticoids and Rates of Incident Diabetes Mellitus and Hypertension in Children with Juvenile Idiopathic Arthritis and Attention-Deficit/Hyperactivity Disorder
Abstract Number: 413

Golimumab in Refractory Uveitis Associated to Juvenile Idiopathic Arthritis. Multicenter Study of 7 Cases and Literature Review
Abstract Number: 414

Proposal for the Definition of Inactivity of Juvenile Idiopathic Arthritis Related Uveitis from the Multinational Interdisciplinary Working Group for Uveitis in Childhood Group (MIWGUC)
Abstract Number: 415

Proposal for a Damage Index for Juvenile Idiopathic Arthritis Related Uveitis from the Multinational Interdisciplinary Working Group for Uveitis in Childhood Group (MIWGUC)
Abstract Number: 416

Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].